1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,140 | 6,200 | 09.01. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.12.25 | LEADS BIOLABS-B (09887): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE OF THE BOARD OF DIRECTORS | 1 | HKEx | ||
| 31.12.25 | LEADS BIOLABS-B (09887): TERMS OF REFERENCE OF THE REMUNERATION COMMITTEE OF THE BOARD OF DIRECTORS | 3 | HKEx | ||
| 31.12.25 | LEADS BIOLABS-B (09887): TERMS OF REFERENCE OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS | 1 | HKEx | ||
| NANJING LEADS BIOLABS Aktie jetzt für 0€ handeln | |||||
| 23.12.25 | Leads Biolabs and Dianthus dose first subject in LBL-047 trial | 2 | Investing.com | ||
| 23.12.25 | Dianthus Therapeutics, Inc.: Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) | 148 | GlobeNewswire (Europe) | LBL-047 (DNTH212) is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress... ► Artikel lesen | |
| 23.12.25 | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - LBL-024 DOSED FIRST PATIENT IN PHASE IB/II TRIAL FOR PLATINUM-RESISTANT OVARIAN CANCER | 2 | HKEx | ||
| 23.12.25 | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - LBL-047 DOSED FIRST SUBJECT IN PHASE I TRIAL | 1 | HKEx | ||
| 17.12.25 | LEADS BIOLABS-B (09887): ARTICLES OF ASSOCIATION | - | HKEx | ||
| 17.12.25 | LEADS BIOLABS-B (09887): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON DECEMBER 17, 2025 | - | HKEx | ||
| 15.12.25 | LEADS BIOLABS-B (09887): INSIDE INFORMATION - PROPOSED IMPLEMENTATION OF H SHARE FULL CIRCULATION PROGRAM BY THE COMPANY | 1 | HKEx | ||
| 01.12.25 | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - LBL-047 RECEIVED IND APPROVAL FROM NMPA | 1 | HKEx | ||
| 28.11.25 | LEADS BIOLABS-B (09887): THE H SHARE AWARD SCHEME | - | HKEx | ||
| 28.11.25 | LEADS BIOLABS-B (09887): PROXY FORM FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON WEDNESDAY, DECEMBER 17, 2025 | 2 | HKEx | ||
| 28.11.25 | LEADS BIOLABS-B (09887): NOTICE OF EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 28.11.25 | LEADS BIOLABS-B (09887): (1) PROPOSED ADOPTION OF THE H SHARE AWARD SCHEME; (2) PROPOSED AUTHORIZATION TO THE BOARD OF DIRECTORS AND/OR THE DELEGATEE ... | - | HKEx | ||
| 27.11.25 | LEADS BIOLABS-B (09887): ANNOUNCEMENT BOOK CLOSURE PERIOD FOR EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 25.11.25 | LEADS BIOLABS-B (09887): (1) PROPOSED ADOPTION OF THE H SHARE AWARD SCHEME; AND (2) PROPOSED CANCELLATION OF THE SUPERVISORY COMMITTEE AND PROPOSED AMENDMENTS ... | 2 | HKEx | ||
| 10.11.25 | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - LBL-024 DOSED FIRST PATIENT IN PHASE II TRIAL OF FIRST-LINE TREATMENT FOR HEPATOCELLULAR CARCINOMA | - | HKEx | ||
| 07.11.25 | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - INCLUSION IN THE MSCI GLOBAL SMALL CAP INDEXES | 1 | HKEx | ||
| 03.11.25 | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - FURTHER ANNOUNCEMENT ON RESEARCH ABSTRACTS ACCEPTED FOR PRESENTATION AT THE 67TH ASH ANNUAL MEETING | 1 | HKEx |
1 2 3 Weiter >>
56 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MOONLAKE IMMUNOTHERAPEUTICS | 18,610 | +29,69 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day | MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application... ► Artikel lesen | |
| CG ONCOLOGY | 54,30 | +29,49 % | CG Oncology Inc.: CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC | - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial... ► Artikel lesen | |
| AKTIS ONCOLOGY | 22,460 | 0,00 % | Aktis Oncology: Erster US-Börsengang des Jahres - die Hintergründe | Die Wall Street kann sich in Kürze über ein weiteres Biotech-Unternehmen freuen. Der Radiopharma-Spezialist Aktis Oncology strebt an die Nasdaq und will mit dem Listing einen dreistelligen Millionen-Dollar-Betrag... ► Artikel lesen | |
| QIAGEN | 41,230 | -0,15 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 26,245 | +12,74 % | Enliven Therapeutics, Inc.: Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts
ELVN-001... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 13,805 | -0,18 % | Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! | Mit Ventyx Biosciences feiert der No Brainer Club eine waschechte Tenbagger-Empfehlung: Nach Übernahmegerüchten springt die Aktie heute im regulären Handel zunächst um rund 30% nach oben, bevor sie... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 24,250 | -4,19 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering | BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. ("Monte Rosa") (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines... ► Artikel lesen | |
| ALUMIS | 19,550 | +7,59 % | What's Going On With Alumis Stock Thursday? | ||
| TRAVERE THERAPEUTICS | 34,580 | -2,87 % | Vifor International AG (CSL Vifor): CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy | FILSPARI® (sparsentan) suggested for IgA Nephropathy patients who are at risk of progressive kidney function loss
ST. GALLEN, Switzerland, and SAN DIEGO, Sept. 26, 2025 /PRNewswire/... ► Artikel lesen | |
| ERASCA | 6,705 | +14,81 % | What's Going With Cancer Biotech Erasca Stock On Thursday? | ||
| AVIDITY BIOSCIENCES | 72,39 | +0,06 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ARCELLX | 66,31 | +3,11 % | UBS initiates Arcellx stock coverage with Buy rating, $100 price target | ||
| ARS PHARMACEUTICALS | 13,130 | +19,91 % | Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? | LONDON (dpa-AFX) - Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and... ► Artikel lesen | |
| COGENT BIOSCIENCES | 35,330 | -0,67 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis | WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| TANGO THERAPEUTICS | 11,820 | +6,92 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor | Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately... ► Artikel lesen |
NANJING LEADS BIOLABS CO LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,900 (+14,52 %) liegt der Kurs bei 7,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANJING LEADS BIOLABS CO LTD finden Sie auf Wallstreet Online.